Utrecht University Study Indicates that Rexahn’s Zoraxel(TM) Could Become New-Class of Drug for Treating Sexual Dysfunction

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), today announced the results of an animal study that further demonstrates Zoraxel as a potential new-class of therapeutic for the effective treatment of sexual dysfunction.